Hansa Biopharma completes enrollment in anti-GBM
The completion of enrollment in the anti-GBM study marks an important milestone for the Company’s expansion outside transplantation. Anti-GBM is a rare immunological disease with a significant unmet medical need.Lund, Sweden January 27, 2020. Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases today announced that the patient enrollment in an investigator-initiated phase 2 study to evaluate safety, tolerability and efficacy of imlifidase in 15 patients with severe Anti-GBM antibody disease has now been completed. A first data read out is expected